- Home
- DVAX vs TXMD Comparison
DVAX vs TXMD Comparison
Compare DVAX & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- TXMD
- Stock Information
- Founded
- DVAX 1996
- TXMD 2008
- Country
- DVAX United States
- TXMD United States
- Employees
- DVAX N/A
- TXMD N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- DVAX Health Care
- TXMD Health Care
- Exchange
- DVAX Nasdaq
- TXMD Nasdaq
- Market Cap
- DVAX N/A
- TXMD 12.8M
- IPO Year
- DVAX 2004
- TXMD N/A
- Fundamental
- Price
- DVAX $10.83
- TXMD $1.19
- Analyst Decision
- DVAX Buy
- TXMD
- Analyst Count
- DVAX 4
- TXMD 0
- Target Price
- DVAX $26.25
- TXMD N/A
- AVG Volume (30 Days)
- DVAX 1.8M
- TXMD 44.6K
- Earning Date
- DVAX 08-05-2025
- TXMD 08-11-2025
- Dividend Yield
- DVAX N/A
- TXMD N/A
- EPS Growth
- DVAX N/A
- TXMD N/A
- EPS
- DVAX N/A
- TXMD N/A
- Revenue
- DVAX $294,620,000.00
- TXMD $1,841,000.00
- Revenue This Year
- DVAX $21.18
- TXMD $427.09
- Revenue Next Year
- DVAX $16.83
- TXMD N/A
- P/E Ratio
- DVAX N/A
- TXMD N/A
- Revenue Growth
- DVAX 24.76
- TXMD 53.55
- 52 Week Low
- DVAX $9.22
- TXMD $0.70
- 52 Week High
- DVAX $14.63
- TXMD $2.44
- Technical
- Relative Strength Index (RSI)
- DVAX 65.22
- TXMD 49.81
- Support Level
- DVAX $10.11
- TXMD $0.98
- Resistance Level
- DVAX $10.38
- TXMD $1.21
- Average True Range (ATR)
- DVAX 0.35
- TXMD 0.09
- MACD
- DVAX 0.10
- TXMD 0.01
- Stochastic Oscillator
- DVAX 94.40
- TXMD 82.48
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.